Plasma cell myeloma

This Phase 2 trial is testing an experimental therapy called LMY-920, which uses a patient's own immune cells (T cells) engineered to recognize and attack cancer cells through a protein called BAFF. The study aims to see if this treatment can shrink tumors or eliminate signs of c…

This phase 1 trial is testing a new gene therapy called UB-VV500 for people with multiple myeloma that has returned or stopped responding to treatment. The therapy works by giving the body genetic instructions to produce its own CAR T cells that target two proteins on myeloma cel…

This trial tests whether a specially engineered donor stem cell transplant, called Orca-Q, can safely treat people with high-risk multiple myeloma that has returned or not responded to prior therapy. The transplant uses donor blood-forming cells and immune cells, with certain T c…

This phase 3 trial tests whether a single infusion of AZD0120, a CAR-T cell therapy that targets two proteins on myeloma cells, can outperform the standard approach of high-dose chemotherapy followed by a stem cell transplant. The study enrolls adults newly diagnosed with multipl…

This early-stage trial is testing an experimental therapy called KIV-318 for people with multiple myeloma that has returned or stopped responding to at least three prior treatments. KIV-318 is a type of CAR-T cell therapy that reprograms a patient's own immune cells to recognize …

Researchers are testing whether adding an experimental drug called F182112 to isatuximab and lenalidomide is safe and can help people with newly diagnosed multiple myeloma who are eligible for a stem cell transplant. The trial enrolls about 10 adults aged 18 to 70. Participants r…

Researchers are testing an experimental oral drug called HP-001 alongside dexamethasone in adults whose multiple myeloma has returned after treatment and has formed tumors outside the bone marrow. Participants take HP-001 capsules once daily for 10 days of each 28-day cycle, plus…

This Phase 3 trial is testing a personalized approach for people with newly diagnosed multiple myeloma who are eligible for a stem cell transplant. After initial treatment with a four-drug combination (isatuximab, iberdomide, bortezomib, and dexamethasone), the next steps—consoli…

This early-phase trial tests an experimental cell therapy called iMagic Injection in adults with relapsed or refractory blood cancers, specifically B-cell non-Hodgkin lymphoma and multiple myeloma. Participants receive a single infusion of engineered immune cells designed to atta…

This study tests a combination of four drugs (isatuximab, iberdomide, bortezomib, and dexamethasone) in 88 adults newly diagnosed with multiple myeloma who cannot or choose not to have a stem cell transplant. The goal is to find the safest dose and see how well the drugs control …

This phase 2 trial tests whether giving two bispecific antibodies (teclistamab and talquetamab) in sequence, along with other drugs, can improve survival in 50 people with high-risk multiple myeloma. Some participants may also receive a stem cell transplant if cancer cells remain…

This study tests whether the drug belantamab mafodotin, given every 6 weeks alongside a steroid, can be safely used in community clinics for patients with relapsed or refractory multiple myeloma. The drug was previously removed from the market after a confirmatory study failed, b…

This phase 3 trial will compare a new treatment, ramantamig plus daratumumab, against two standard drug combinations for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. The study aims to see if the new combo can keep the cancer from p…

This early-phase trial tests a new type of CAR-T cell therapy that targets two cancer markers (BCMA and GPRC5D) in people with high-risk multiple myeloma or plasmacytoma. The goal is to see if it is safe and can control the disease as a first treatment. About 20 participants will…

This phase 2 trial tests whether adding elranatamab to a standard three-drug regimen can improve outcomes for people newly diagnosed with ultra-high-risk multiple myeloma. Researchers will give 15 participants elranatamab, isatuximab, bortezomib, and lenalidomide, and measure how…

This study tests a new type of immunotherapy called CAR T cells that are designed to recognize several different targets on multiple myeloma cancer cells. The treatment involves taking a patient's own immune cells, modifying them in a lab to better attack the cancer, and infusing…

This early-stage trial tests a personalized dendritic cell vaccine in 10 multiple myeloma patients who are already in very good remission. The vaccine is designed to train the immune system to keep the cancer from returning. The main goal is to see if the vaccine is safe, with a …

This early-stage trial is testing a new type of cell therapy called universal CAR-T cells for people with multiple myeloma that has not been cured by standard treatments. The therapy uses donor cells modified to target myeloma cells, aiming to be a ready-made option. The study wi…

This phase 2 trial is testing a new drug called CM336, given alongside standard therapy, for people with high-risk multiple myeloma. The study will include 46 adults aged 18 to 75. The main goal is to see if the combination can reduce cancer cells to very low levels (MRD negativi…

This pilot study explores whether a structured heart-health assessment can be done successfully and on time for adults with multiple myeloma who are starting a new line of treatment. Participants will be assigned by chance to receive the assessment either from a clinician embedde…

This early-stage trial is testing a new drug called BP2202 in 24 people with multiple myeloma that has come back or no longer responds to standard treatments. The main goal is to see if BP2202 is safe and to find the best dose. Researchers will also watch for any signs that the d…

This phase II trial is testing whether a new investigational drug called IBI3003, when combined with an existing anti-CD38 antibody (daratumumab), can improve outcomes for people with multiple myeloma. The study includes patients with relapsed or refractory disease, as well as ne…

This phase II trial is testing whether combining teclistamab, an antibody that helps immune cells attack myeloma cells, with pomalidomide, a drug that slows cancer growth, can control multiple myeloma in people whose disease has returned or stopped responding after 1-3 prior trea…

This phase 2 trial tests a drug called linvoseltamab in 34 people with multiple myeloma whose cancer returned after BCMA CAR T-cell therapy. Linvoseltamab is a bispecific antibody that helps the immune system attack myeloma cells. The main goal is to see how many patients respond…

This early-phase trial tests a new type of CAR T-cell therapy called FT836, given together with the drug daratumumab, in 12 adults with multiple myeloma that has come back or stopped responding to at least three prior treatments. The main goal is to see if the combination is safe…

This trial asks whether a reduced dose of belantamab mafodotin, combined with pomalidomide and dexamethasone, can control relapsed or refractory multiple myeloma as effectively as the standard dose while causing fewer side effects. Adults with this blood cancer who have had at le…

This trial is testing whether belantamab, a drug used for multiple myeloma, can be given as a quick injection under the skin instead of a slow drip into a vein. About 22 adults with multiple myeloma who are already on standard maintenance therapy will receive both forms in a cros…

This phase 3 trial tests whether combining two immunotherapies, teclistamab and talquetamab, can eliminate residual cancer cells in multiple myeloma patients who have undergone a stem cell transplant. Participants with detectable minimal residual disease (MRD) are randomly assign…

This trial tests whether a combination of isatuximab plus a reduced-intensity version of standard chemotherapy (VRDlite) can effectively treat newly diagnosed multiple myeloma in frail older adults who are not candidates for a stem cell transplant. The study focuses on patients w…

This early-phase trial tests whether giving the drug iberdomide before collecting a patient's T cells can improve the fitness of those cells for CAR-T therapy. The study enrolls adults with relapsed or refractory multiple myeloma who are already scheduled for standard CAR-T treat…

This phase 3 trial is testing whether an experimental drug called etentamig, combined with pomalidomide, can control multiple myeloma that has come back or stopped responding to treatment. About 520 adults who have already tried 1 to 3 prior therapies will be randomly assigned to…

This trial tests whether adding a small dose of total body radiation to standard CAR T-cell therapy can help the immune cells grow stronger and last longer in the body. It enrolls adults with relapsed or hard-to-treat diffuse large B-cell lymphoma or multiple myeloma who are alre…

This trial tests whether a mechanical, spring-driven device called FreedomEDGE® can safely and effectively deliver daratumumab, a standard treatment for multiple myeloma and amyloidosis. Currently, nurses give these injections by hand, which can be physically demanding. About 100…

This early-phase trial is testing whether combining two targeted drugs—talquetamab and belantamab mafodotin—can safely control multiple myeloma that has returned or stopped responding to prior treatments. The study enrolls adults with myeloma who have already tried at least one p…

This study tests a combination of four drugs—sotoclax, carfilzomib, lenalidomide, and dexamethasone (called SonKRd)—in people newly diagnosed with multiple myeloma that has a specific genetic change called t(11;14). Participants must be healthy enough for a stem cell transplant. …

This phase 2 trial tests an investigational drug called YKST02 in adults with multiple myeloma that has relapsed or stopped responding to prior treatments. YKST02 is a bispecific antibody designed to bind both myeloma cells and immune T cells, potentially helping the immune syste…

This study tests two chemotherapy-free treatments for people newly diagnosed with AL amyloidosis, a rare blood disorder. The choice of treatment depends on whether the patient has a specific genetic change called t(11;14). Those with t(11;14) receive a daily pill called sonrotocl…

This phase 1 trial is testing a new kind of CAR-T cell therapy, called LMY-922, for people with certain blood cancers that have not responded to standard treatments. The therapy uses donor immune cells engineered to target a protein called BAFF on cancer cells. The study aims to …

This Phase 3 trial tests whether adding the drug Teclistamab to a standard treatment regimen (Daratumumab, Lenalidomide, Bortezomib, Dexamethasone) improves outcomes for newly diagnosed multiple myeloma patients eligible for stem cell transplant. About 399 adults aged 18-70 will …

This phase 2 trial compares two drug combinations for people newly diagnosed with multiple myeloma who are not eligible for or have deferred a stem cell transplant. One group gets the experimental drug elranatamab plus standard medications (lenalidomide, bortezomib, dexamethasone…

This phase 2 trial is testing whether different dosing schedules of belantamab mafodotin, when combined with bortezomib and dexamethasone, can reduce the risk of serious eye problems while still controlling multiple myeloma. About 150 adults with relapsed or refractory multiple m…

This study tests a combination of two drugs, belantamab mafodotin and mezigdomide, in 44 adults with multiple myeloma whose cancer returned after treatment with CAR-T cells or bispecific antibodies. The goal is to see if the combo can control the cancer longer. The trial starts w…

This early-phase trial tests a new cell therapy called RN9101 in 19 adults with relapsed or refractory multiple myeloma, a blood cancer that has not responded to at least two prior treatments. RN9101 is a type of CAR-T cell therapy given as a single intravenous infusion. The main…

This early-phase trial is testing DQ1001, a ready-made CAR-T cell therapy that targets two proteins (BCMA and GPRC5D) on myeloma cells. It is designed for patients whose multiple myeloma has returned or stopped responding to at least three prior treatments. The study will enroll …

This early-stage trial tests the safety of a new CAR T-cell therapy, UF-KURE-BCMA, in 12 adults with multiple myeloma that has returned or not responded to other treatments. The therapy uses specially engineered immune cells to target and attack cancer cells. The main goal is to …

This study tests a new five-drug combination for people newly diagnosed with a high-risk form of multiple myeloma. The drugs include etentamig, isatuximab, bortezomib, lenalidomide, and dexamethasone. The trial will enroll 220 participants and first check safety, then see if the …

This study tests a new drug called TQB2934 in 260 people whose multiple myeloma has returned or stopped responding to treatment. Participants are randomly assigned to receive either TQB2934 or one of several standard treatments chosen by their doctor. The main goal is to see if T…

This study tests whether the drug emapalumab can prevent severe side effects (cytokine release syndrome and nerve-related toxicity) in people with lymphoma or multiple myeloma receiving bispecific antibody therapy. About 60 adults will take emapalumab before their cancer treatmen…

This Phase 2 trial tests a new drug called QLS4131, given under the skin, in combination with other medications for people with malignant plasma cell neoplasms like multiple myeloma. The study will compare different drug combinations to see which works best at shrinking tumors an…

This study tests whether adding thiotepa to the standard melphalan treatment before a stem cell transplant can lower the chance of multiple myeloma coming back within a year. It includes 204 adults aged 18-70 whose cancer was not fully cleared by prior therapy. Participants are r…

This early-phase trial tests a new gene therapy called QI-019B for people with multiple myeloma that has returned or not responded to at least two prior treatments. The therapy works by creating cancer-fighting CAR-T cells directly inside the patient's body. The study will enroll…

This early-stage trial tests a new drug called BR101 in 10 people with multiple myeloma that has returned or not responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look at whether the drug helps shrink the ca…

This early-phase study tests a new treatment called CAR19-BCMA CAR-T for people with certain blood cancers (plasma cell neoplasms or lymphomas/leukemias) that have returned or not responded to at least three prior treatments. The therapy uses a patient's own immune cells, modifie…

This early-stage study tests a new treatment called Equecabtagene autoleucel for people with multiple myeloma that has returned or stopped responding to at least three prior therapies. The treatment uses a patient's own immune cells, modified to attack a protein called BCMA on my…

This trial is for adults with multiple myeloma or Waldenstrom macroglobulinaemia. It tests whether giving certain drugs less often can control the disease as well as the standard schedule. The goal is to find the best balance between effectiveness and quality of life. About 400 p…

This early-phase trial tests a personalized cell therapy called CART-BCMA in 3 Thai patients with multiple myeloma that has returned or stopped responding to at least three prior treatments. The therapy uses the patient's own immune cells, modified in a lab to target and kill mye…

This early-phase trial is testing a new drug called IBI3003 in about 360 people with multiple myeloma that has returned or no longer responds to standard treatments. The study has two parts: first, finding the safest and most effective dose, and then testing how well it works. Pa…

This early-stage trial is testing a new treatment called SENL103 for people with multiple myeloma that has returned or not responded to standard treatments. The treatment uses a patient's own immune cells, modified to target and attack cancer cells. The study will enroll 24 parti…

This early-phase study tests whether giving a bispecific antibody (CM336) before CAR-T cell therapy can improve outcomes for people with relapsed or refractory multiple myeloma — a blood cancer that has stopped responding to standard treatments. Ten adults will receive the antibo…

This early-phase trial tests a new cell therapy called SL4903 for people with multiple myeloma that has come back or stopped responding to standard treatments. The therapy uses a patient's own immune cells, modified to better attack the cancer. The main goal is to check safety an…

This early-phase trial tests a new treatment called LVIVO-TaVec400 for people with multiple myeloma that has come back or not responded to standard treatments. The therapy uses the patient's own immune cells, modified to better attack cancer cells. The study will enroll 38 adults…

This study tests a new treatment called BCMA-GPRC5D CAR-T for people with multiple myeloma that has come back or not responded to at least three prior treatments. The therapy uses a patient's own immune cells, modified to attack two cancer targets. The goal is to see if it is saf…

This early-phase trial tests a new type of immune cell therapy called GPRC5D CAR-T in 18 people with relapsed or treatment-resistant plasma cell disorders, such as multiple myeloma. The therapy involves giving patients a single infusion of their own modified immune cells designed…

This early-phase trial tests a new mRNA-based drug called WGb-0302 in 20 adults with recurrent or treatment-resistant multiple myeloma and other blood cancers. The therapy uses lipid nanoparticles to deliver mRNA that targets BCMA, a protein on cancer cells. The main goals are to…

This early-phase trial tests a personalized treatment called IASO104 for people with relapsed or refractory multiple myeloma, a blood cancer that has not responded to standard therapies. IASO104 is made from a patient's own immune cells, which are genetically modified to recogniz…

This Phase 2 trial is testing a combination of three drugs—mezigdomide, carfilzomib, and dexamethasone—in 70 adults with relapsed or refractory multiple myeloma. The goal is to see if this combo can slow or stop the cancer from growing. Participants must have already tried lenali…

This study compares a four-drug regimen (isatuximab plus standard VRD) against the standard three-drug VRD in 117 newly diagnosed multiple myeloma patients who are not eligible for transplant and have high-risk features. The goal is to see if adding isatuximab leads to more patie…

This early study tests a new treatment called IASO206 for people with multiple myeloma that has come back or stopped responding to standard therapies. IASO206 is a type of CAR-T therapy that uses a patient's own immune cells to attack cancer cells. The trial will enroll 12 adults…

This study follows 159 Chinese patients with triple-class exposed relapsed/refractory multiple myeloma who are taking elranatamab in routine care. Researchers will track how well the drug controls the cancer, including response rates and survival. The goal is to see if elranatama…

This early-phase trial tests whether giving a bispecific antibody (QLS32015) before CAR-T cell therapy can improve outcomes for 20 adults with relapsed/refractory multiple myeloma. The study measures how many patients respond and tracks side effects. It is a single-arm, open-labe…

This Phase 3 trial compares a new drug called CM336 against standard treatments for people with relapsed or refractory multiple myeloma who have already tried at least two prior therapies. About 280 participants will be randomly assigned to receive either CM336 or a standard-of-c…

This early-phase trial tests a new drug called BT02, a monoclonal antibody, in 116 adults with relapsed or refractory blood cancers like leukemia, lymphoma, or multiple myeloma. Participants receive the drug by IV every 2-3 weeks for up to two years. The main goals are to check s…

This study aims to personalize treatment for people newly diagnosed with multiple myeloma who have an extra copy of chromosome 1q, a marker of higher risk. Researchers will use a scoring system based on factors like disease stage and lab results to classify patients into low, int…

This study tests whether musculoskeletal ultrasound can reliably detect bone, joint, and soft-tissue problems in adults with blood cancers like leukemia, lymphoma, and multiple myeloma. Participants with symptoms such as bone pain, joint swelling, or muscle pain will receive a de…

This study tests a new imaging tracer called [18F]FAPI-74, which attaches to a protein found on cells in tumors and scarred or inflamed tissue. Researchers want to see if it can show these areas more clearly than current scans. About 770 adults with various cancers or non-cancer …

This study tests a new blood test that looks for DNA fragments in the blood (called cfDNA) to detect multiple myeloma and its early forms (MGUS and smoldering myeloma) in people over 40. The test uses machine learning to tell the difference between healthy individuals and those w…

This study tests a new radioactive tracer for PET/CT scans that targets a protein called GPRC5D found on multiple myeloma cells. About 50 adults with plasma cell disorders, including multiple myeloma, will receive the tracer and then undergo imaging. The goal is to see if this me…

This study explores whether a PET/MR scan using a radioactive tracer called 18F-Florbetaben can detect amyloid deposits—abnormal protein clumps that can damage organs—in people with certain blood disorders. Participants receive a single injection of the tracer followed by a whole…

This study tests a new type of PET/CT scan that uses a special tracer (68Ga-BCMA nanobody) to find multiple myeloma lesions in the body. Researchers will compare it to the standard FDG-PET/CT scan in 30 patients with newly diagnosed or relapsed multiple myeloma. The goal is to se…

This study looks at whether people with multiple myeloma can safely give themselves the drug daratumumab at home instead of going to the hospital. About 50 patients will take turns receiving the injection at home and at the clinic to compare the two approaches. The goal is to see…

This study tests if taking fish oil by mouth can prevent or lessen nerve damage (peripheral neuropathy) caused by the chemotherapy drug bortezomib in people with multiple myeloma. Researchers will compare nerve health in 200 patients who take fish oil versus those who don't. The …

This study tests whether orthopedic check-ups and custom exercise plans can improve physical function and rehabilitation in people with multiple myeloma who have bone lesions. About 71 newly diagnosed patients will receive ongoing bone stability assessments and tailored exercise …

This study tests whether adding a controlled breathing program to a standard exercise routine improves heart and lung function in people with multiple myeloma. Twenty-six adults currently on treatment will take part in a 6-week program. One group will do breathing exercises at ho…

This study looks at whether adding a controlled breathing routine to a standard exercise program can reduce physical symptoms like pain and fatigue in adults with multiple myeloma. About 32 participants will take part in a 6-week program, with some doing extra breathing exercises…

This study looks at whether a special education program and a check-in on caregivers' own needs can boost the quality of life for people caring for someone with multiple myeloma. About 27 caregivers will take part. The goal is to see if this extra support helps them feel better a…

This study looks at whether a 12-week resistance exercise program can improve quality of life, reduce frailty, and boost mental health in people with multiple myeloma. Fifty patients will be split into two groups: one doing supervised exercise and the other doing the same exercis…

Multiple myeloma is a blood cancer in which abnormal plasma cells build up in bone marrow, and inflammation may shape how the disease behaves. Researchers at Assiut University plan to study 60 people newly diagnosed with myeloma before any anti-myeloma treatment begins. They will…

This study will review medical records of 300 UK patients with newly diagnosed multiple myeloma who cannot have a stem cell transplant and are treated with a three-drug combination (daratumumab, lenalidomide, and dexamethasone). The goal is to see how well this therapy works in e…

This pilot study is testing whether wearable patch monitors can help detect heart problems early in adults undergoing treatment for breast cancer, blood cancers, or multiple myeloma. Participants will wear two patches—one that tracks heart rhythm continuously and another that rec…

This study is looking at whether a special type of whole-body MRI can help predict how well people with multiple myeloma will do after a stem cell transplant. The MRI measures changes in bone marrow and fat content in the bones, which might indicate if the cancer is more likely t…

This study looks at blood cancer patients who carry drug-resistant bacteria in their gut. Researchers want to find out who is most likely to get a serious infection from these bacteria. They will collect rectal swabs and track patients for 90 days to build a prediction tool. The …

This study follows people with relapsed or refractory multiple myeloma who are scheduled to receive BCMA CAR-T therapy, a type of cell treatment. Researchers will test memory, attention, and other thinking skills at the start and again at 1, 6, and 12 months after the infusion. T…

This study aims to enroll 10,000 adults across the United States to help identify genetic variants linked to blood cancers such as leukemia, lymphoma, and myeloma. Participants complete online health surveys and provide a saliva sample by mail. Researchers will analyze the DNA to…

This study follows adults with multiple myeloma or B-cell lymphoma who receive CAR-T cell therapy, a powerful immune treatment. Researchers track infections that occur in the first year after treatment, looking at how common they are, what causes them, and which factors raise the…

This study tests whether a blood test using mass spectrometry can detect minimal residual disease (tiny amounts of cancer left after treatment) in multiple myeloma patients. Currently, doctors must take bone marrow samples, which is painful and inconvenient. The blood test would …

This observational study will review medical records of about 100 adults with multiple myeloma that has returned after initial treatment. Researchers want to see how well belantamab mafodotin given with other drugs (bortezomib and dexamethasone, or pomalidomide and dexamethasone)…

This pilot study tests a new imaging method called PET-enabled dual-energy CT to measure bone and soft tissue in the bone marrow. It will include 45 adults: some with multiple myeloma scheduled for CAR T-cell therapy and some healthy volunteers. The goal is to see if this new met…

This study looks at why some people with blood cancers like multiple myeloma or lymphoma choose not to receive treatment at home, or are not eligible for it. Researchers will interview patients, their caregivers, and healthcare staff, and review medical records and questionnaires…

This early-phase study looks at how the drug combination BVd (belantamab mafodotin, bortezomib, and dexamethasone) is processed by the body in people with multiple myeloma who also have moderate liver problems. About 20 participants will be enrolled to compare drug levels and saf…

This Italian registry will follow 50 adults with relapsed/refractory multiple myeloma who are receiving elranatamab as part of their standard care. The goal is to track how many infections occur during the first year of treatment. The study does not test a new drug but aims to ga…

This study will follow 225 blood cancer patients receiving CAR-T therapy, bispecific antibodies, or high-dose chemotherapy with stem cell transplant. Researchers will test memory, attention, and thinking skills before treatment and up to 3 years after. The goal is to understand h…

This study looks at how people with blood cancers (like leukemia, lymphoma, or myeloma) in France use complementary and alternative medicines (CAM), such as acupuncture or herbal remedies. Researchers will survey 85 patients and interview some to understand why they use these the…

This study will check if old tissue samples from 15 patients with extramedullary multiple myeloma can be used to find new biomarkers. Researchers will look at the samples and medical records to see if they are good enough for future research. No new treatments or tests are given—…

This study will check if stored tissue samples from 20 people with a specific type of multiple myeloma (t(4-14)) can be used to find new biomarkers. No new treatments or tests are given. The goal is to see if the samples are good enough for research.

This Phase 1 trial tests QL2109, a biosimilar to the multiple myeloma drug Darzalex, in 102 healthy Chinese men. The goal is to see if the body processes QL2109 similarly to Darzalex and to check for side effects. It does not test the drug's ability to treat cancer.

This early study tests a new PET imaging agent called 68Ga-NOTA-BCMA to see if it can safely and accurately show where anti-BCMA CAR-T cells go in the body and how long they last. Ten adults with multiple myeloma who are scheduled for CAR-T therapy will receive the tracer and und…

This observational study follows 162 patients with blood cancers who are receiving either a stem cell transplant or CAR-T therapy. Researchers will use a questionnaire to measure how symptoms and quality of life change from the start of hospital stay to discharge. The goal is to …

This study looks at how a personalized strength training program affects people with different cancers, including lung, colon, breast, and blood cancers. 150 adults will either do supervised strength training plus home exercises, or just home exercises, for 12 weeks. Researchers …

This study creates a registry of 500 cancer patients receiving immunotherapy to better understand and manage immune-related side effects (irAEs). Researchers will collect data on who gets these side effects, how they present, and what treatments work best. The goal is to improve …